Mirum Pharmaceuticals, Inc. Common Stock
MIRMMirum Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing therapies for rare and orphan diseases, particularly those affecting the liver. The company aims to address unmet medical needs through innovative and targeted treatments.
Company News
Mirum Pharmaceuticals has seen nearly 70% stock growth in 2025, with its flagship drug Livmarli driving sales and potential for continued expansion in 2026, supported by promising pipeline candidates volixibat and MRM-3379.
Mirum (MIRM) posts positive interim data from two phase IIb studies evaluating volixibat in patients with primary biliary cholangitis and primary sclerosing cholangitis. Stock rises.
In the preceding three months, 10 analysts have released ratings for Mirum Pharmaceuticals (NASDAQ:MIRM), presenting a wide array of perspectives from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish...
